Advertisement

Statin Therapy in Stroke Prevention: A Meta-analysis Involving 121,000 Patients

      Abstract

      Purpose

      More than 120,000 patients now have taken part in randomized trials evaluating statin therapy for stroke prevention. We aimed to conduct a comprehensive review of all randomized trials and determine the therapeutic potential of statins for all strokes.

      Methods

      We searched 10 electronic databases (from inception to December 2006). We additionally contacted study authors and authors of previous reviews. We extracted data on study characteristics and outcomes related to all-cause mortality, all-stroke incidence, specific type of strokes, and cholesterol changes. We pooled data using a random-effects model and conducted meta-regression.

      Results

      We included 42 trials assessing statin therapy for all-stroke prevention (n=121,285), resulting in a pooled relative risk (RR) of 0.84 (95% confidence interval [CI], 0.79-0.91). The pooled RR of statin therapy for all-cause mortality (n=116,080) was 0.88 (95% CI, 0.83-0.93). Each unit increase in low-density lipoprotein (LDL) resulted in a 0.3% increased RR of death (P=.02). Seventeen trials evaluated statins on cardiovascular death (n=57,599, RR 0.81, 95% CI, 0.74-0.90), and 11 evaluated nonhemorrhagic cerebrovascular events (n=58,604, RR 0.81, 95% CI, 0.69-0.94). Eleven trials reported hemorrhagic stroke incidence (total n=54,334, RR 0.94, 95% CI, 0.68-1.30) and 21 trials reported on fatal strokes (total n=82,278, RR 0.99, 95% CI, 0.80-1.21). Only one trial reported on statin therapy for secondary prevention.

      Conclusions

      Statin therapy provides high levels of protection for all-cause mortality and nonhemorrhagic strokes. This overview reinforces the need to consider prolonged statin treatment in patients at high risk of major vascular events, but caution remains for patients at risk of bleeds.

      Keywords

      To read this article in full you will need to make a payment

      References

        • American Heart Association
        Heart Disease and Stroke Statistics—2006 Update.
        American Heart Association, Dallas, TX2006
      1. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts.
        Lancet. 1995; 346: 1647-1653
        • Iso H.
        • Jacobs Jr, D.R.
        • Wentworth D.
        • et al.
        Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial.
        N Engl J Med. 1989; 320: 904-910
      2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1994; 344: 1383-1389
        • Sacks F.M.
        • Pfeffer M.A.
        • Moye L.A.
        • et al.
        The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
        N Engl J Med. 1996; 335: 1001-1009
        • White H.D.
        • Simes R.J.
        • Anderson N.E.
        • et al.
        Pravastatin therapy and the risk of stroke.
        N Engl J Med. 2000; 343: 317-326
        • Heart Protection Study Collaborative Group
        Mrc/bhf heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
        Lancet. 2002; 360: 7-22
        • Schwartz G.G.
        • Olsson A.G.
        • Ezekowitz M.D.
        • et al.
        Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
        JAMA. 2001; 285: 1711-1718
        • Sever P.S.
        • Dahlof B.
        • Poulter N.R.
        • et al.
        Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the anglo-scandinavian cardiac outcomes trial–lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial.
        Lancet. 2003; 361: 1149-1158
        • Collins R.
        • Armitage J.
        • Parish S.
        • et al.
        Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions.
        Lancet. 2004; 363: 757-767
        • Bucher H.C.
        • Griffith L.E.
        • Guyatt G.H.
        Effect of hmgcoa reductase inhibitors on stroke.
        Ann Intern Med. 1998; 128: 89-95
        • Hebert P.R.
        • Gaziano J.M.
        • Chan K.S.
        • Hennekens C.H.
        Cholesterol lowering with statin drugs, risk of stroke, and total mortality.
        JAMA. 1997; 278: 313-321
        • Blauw G.J.
        • Lagaay A.M.
        • Smelt A.H.
        • Westendorp R.G.
        Stroke, statins, and cholesterol.
        Stroke. 1997; 28: 946-950
        • Briel M.
        • Studer M.
        • Glass T.R.
        • Bucher H.C.
        Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials.
        Am J Med. 2004; 117: 596-606
        • Vaughan C.J.
        • Gotto Jr, A.M.
        • Basson C.T.
        The evolving role of statins in the management of atherosclerosis.
        J Am Coll Cardiol. 2000; 35: 1-10
        • Briel M.
        • Nordmann A.J.
        • Bucher H.C.
        Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and meta-analyses.
        Curr Opin Lipidol. 2005; 16: 601-605
        • Bucher H.C.
        • Griffith L.E.
        • Guyatt G.H.
        Systematic review on the risk and benefit of different cholesterol-lowering interventions.
        Arterioscler Thromb Vasc Biol. 1999; 19: 187-195
        • Studer M.
        • Briel M.
        • Leimenstoll B.
        • et al.
        Effect of different antilipidemic agents and diets on mortality: a systematic review.
        Arch Intern Med. 2005; 165: 725-730
        • Zhou Z.
        • Rahme E.
        • Pilote L.
        Are statins created equal?.
        Am Heart J. 2006; 151: 273-281
        • Baigent C.
        • Keech A.
        • Kearney P.M.
        • et al.
        Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
        Lancet. 2005; 366: 1267-1278
      3. NICE. Assessment report: coronary heart disease—statins. Available at: http://www.Nice.Org.Uk/pdf/statins_assessment_report.Pdf 2005. Accessed November 13, 2007.

        • Meade M.O.
        • Guyatt G.H.
        • Cook R.J.
        • et al.
        Agreement between alternative classifications of acute respiratory distress syndrome.
        Am J Respir Crit Care Med. 2001; 163: 490-493
        • Sheehe P.R.
        Combination of log relative risk in retrospective studies of disease.
        Am J Public Health Nations Health. 1966; 56: 1745-1750
        • Fleiss J.L.
        The statistical basis of meta-analysis.
        Stat Methods Med Res. 1993; 2: 121-145
        • DerSimonian R.
        • Laird N.
        Meta-analysis in clinical trials.
        Control Clin Trials. 1986; 7: 177-188
        • Higgins J.P.
        • Thompson S.G.
        Quantifying heterogeneity in a meta-analysis.
        Stat Med. 2002; 21: 1539-1558
        • Thompson S.G.
        • Higgins J.P.
        How should meta-regression analyses be undertaken and interpreted?.
        Stat Med. 2002; 21: 1559-1573
      4. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors.
        Am J Cardiol. 1993; 72: 1031-1037
      5. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS).
        Lancet. 1994; 344: 633-638
      6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
        N Engl J Med. 1998; 339: 1349-1357
      7. Results of the low-dose (20 mg) pravastatin gissi prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge?.
        Ital Heart J. 2000; 1: 810-820
      8. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT).
        JAMA. 2002; 288: 2998-3007
        • Adams Jr, H.P.
        Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke.
        Cerebrovasc Dis. 1995; 5: 171-177
        • Amarenco P.
        • Bogousslavsky J.
        • Callahan 3rd, A.
        • et al.
        High-dose atorvastatin after stroke or transient ischemic attack.
        N Engl J Med. 2006; 355: 549-559
        • Asselbergs F.W.
        • Diercks G.F.
        • Hillege H.L.
        • et al.
        Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
        Circulation. 2004; 110: 2809-2816
        • Athyros V.G.
        • Papageorgiou A.A.
        • Mercouris B.R.
        • et al.
        Treatment with atorvastatin to the national cholesterol educational program goal versus ‘usual’ care in secondary coronary heart disease prevention.
        Curr Med Res Opin. 2002; 18: 220-228
        • Bestehorn H.P.
        • Rensing U.F.
        • Roskamm H.
        • et al.
        The effect of simvastatin on progression of coronary artery disease.
        Eur Heart J. 1997; 18: 226-234
        • Blankenhorn D.H.
        • Azen S.P.
        • Kramsch D.M.
        • et al.
        Coronary angiographic changes with lovastatin therapy.
        Ann Intern Med. 1993; 119: 969-976
        • Colhoun H.M.
        • Betteridge D.J.
        • Durrington P.N.
        • et al.
        Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial.
        Lancet. 2004; 364: 685-696
        • Crouse 3rd, J.R.
        • Byington R.P.
        • Bond M.G.
        • et al.
        Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-ii).
        Am J Cardiol. 1995; 75: 455-459
        • Downs J.R.
        • Clearfield M.
        • Weis S.
        • et al.
        Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS.
        JAMA. 1998; 279: 1615-1622
        • Hedblad B.
        • Wikstrand J.
        • Janzon L.
        • et al.
        Low-dose metoprolol cr/xl and fluvastatin slow progression of carotid intima-media thickness: Main results from the beta-blocker cholesterol-lowering asymptomatic plaque study (BCAPS).
        Circulation. 2001; 103: 721-1726
        • Holdaas H.
        • Fellstrom B.
        • Jardine A.G.
        • et al.
        Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.
        Lancet. 2003; 361: 2024-2031
        • Jukema J.W.
        • Bruschke A.V.
        • van Boven A.J.
        • et al.
        Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels.
        Circulation. 1995; 91: 2528-2540
        • Koren M.J.
        • Hunninghake D.B.
        Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the Alliance study.
        J Am Coll Cardiol. 2004; 44: 1772-1779
        • Liem A.H.
        • van Boven A.J.
        • Veeger N.J.
        • et al.
        Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial.
        Eur Heart J. 2002; 23: 1931-1937
        • Makuuchi H.
        • Furuse A.
        • Endo M.
        • et al.
        Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery.
        Circ J. 2005; 69: 636-643
        • Mercuri M.
        • Bond M.G.
        • Sirtori C.R.
        • et al.
        Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study.
        Am J Med. 1996; 101: 627-634
        • Mohler 3rd, E.R.
        • Hiatt W.R.
        • Creager M.A.
        Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.
        Circulation. 2003; 108: 1481-1486
        • Nakagawa T.
        • Kobayashi T.
        • Awata N.
        • et al.
        Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the prevention of coronary sclerosis (PCS) study.
        Int J Cardiol. 2004; 97: 107-114
        • Nakamura H.
        • Arakawa K.
        • Itakura H.
        • et al.
        Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial.
        Lancet. 2006; 368: 1155-1163
        • O’Rourke B.
        • Barbir M.
        • Mitchell A.G.
        • et al.
        Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantation: results of a randomised double blind placebo controlled study.
        Int J Cardiol. 2004; 94: 235-240
        • Petronio A.S.
        • Amoroso G.
        • Limbruno U.
        • et al.
        Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: a randomized study with intravascular ultrasound.
        Am Heart J. 2005; 149: 520-526
        • Salonen R.
        • Nyyssonen K.
        • Porkkala E.
        • et al.
        Kuopio Atherosclerosis Prevention Study (KAPS).
        Circulation. 1995; 92: 1758-1764
        • Serruys P.W.
        • de Feyter P.
        • Macaya C.
        • et al.
        Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.
        JAMA. 2002; 287: 3215-3222
        • Shepherd J.
        • Blauw G.J.
        • Murphy M.B.
        • et al.
        Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.
        Lancet. 2002; 360: 1623-1630
        • Shepherd J.
        • Cobbe S.M.
        • Ford I.
        • et al.
        Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
        N Engl J Med. 1995; 333: 1301-1307
        • Stone P.H.
        • Lloyd-Jones D.M.
        • Kinlay S.
        • et al.
        Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the vascular basis for the treatment of myocardial ischemia study.
        Circulation. 2005; 111: 1747-1755
        • Teo K.K.
        • Burton J.R.
        • Buller C.E.
        • et al.
        Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the simvastatin/enalapril coronary atherosclerosis trial (SCAT).
        Circulation. 2000; 102: 1748-1754
        • Wanner C.
        • Krane V.
        • Marz W.
        • et al.
        Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
        N Engl J Med. 2005; 353: 238-248
        • Waters D.
        • Higginson L.
        • Gladstone P.
        • et al.
        Effects of monotherapy with an hmg-coa reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography.
        Circulation. 1994; 89: 959-968
        • Yokoi H.
        • Nobuyoshi M.
        • Mitsudo K.
        • et al.
        Three-year follow-up results of angiographic intervention trial using an hmg-coa reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study.
        Circ J. 2005; 69: 875-883
        • Zanchetti A.
        • Crepaldi G.
        • Bond M.G.
        • et al.
        Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS—a randomized double-blind trial.
        Stroke. 2004; 35: 2807-2812
        • Sakamoto T.
        • Kojima S.
        • Ogawa H.
        • et al.
        Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese.
        Am J Cardiol. 2006; 97: 1165-1171
        • Iwashita M.
        • Matsushita Y.
        • Sasaki J.
        • et al.
        Relation of serum total cholesterol and other factors to risk of cerebral infarction in Japanese men with hypercholesterolemia.
        Circ J. 2005; 69: 1-6
        • Goldstein L.B.
        • Amarenco P.
        • Bogousslavsky J.
        • et al.
        Statins for secondary stroke prevention in patients without known coronary heart disease: the jury is still out.
        Cerebrovasc Dis. 2004; 18: 1-2
        • Song F.
        • Altman D.G.
        • Glenny A.M.
        • Deeks J.J.
        Validity of indirect comparison for estimating efficacy of competing interventions: Empirical evidence from published meta-analyses.
        BMJ. 2003; 326: 472
        • Silva M.A.
        • Swanson A.C.
        • Gandhi P.J.
        • Tataronis G.R.
        Statin-related adverse events: a meta-analysis.
        Clin Ther. 2006; 28: 26-35
        • Trubelja N.
        • Vaughan C.
        • Coplan N.L.
        The role of statins in preventing stroke.
        Prev Cardiol. 2005; 8: 98-101